JETEMA Co. Ltd
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks. JETEMA, Co., Ltd. was founded in 2… Read more
JETEMA Co. Ltd (216080) - Total Liabilities
Latest total liabilities as of September 2025: ₩156.25 Billion KRW
Based on the latest financial reports, JETEMA Co. Ltd (216080) has total liabilities worth ₩156.25 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JETEMA Co. Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how JETEMA Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JETEMA Co. Ltd Competitors by Total Liabilities
The table below lists competitors of JETEMA Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GFPT Public Company Limited
BK:GFPT
|
Thailand | ฿6.34 Billion |
|
Dorsel Holdings Ltd
TA:DRSH
|
Israel | ₪791.11 Million |
|
Inogen Inc
NASDAQ:INGN
|
USA | $109.83 Million |
|
Zippy Technology Corp
TW:2420
|
Taiwan | NT$1.69 Billion |
|
Fifth Era Acquisition Corp I Class A Ordinary Shares
NASDAQ:FERA
|
USA | $13.67 Million |
|
Brazil Potash Corp.
NYSE:GRO
|
USA | $6.39 Million |
|
Tongling Jieya Biologic Technology Co. Ltd.
SHE:301108
|
China | CN¥330.27 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down JETEMA Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JETEMA Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JETEMA Co. Ltd (2017–2024)
The table below shows the annual total liabilities of JETEMA Co. Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩151.29 Billion | -11.62% |
| 2023-12-31 | ₩171.17 Billion | +30.26% |
| 2022-12-31 | ₩131.41 Billion | +40.75% |
| 2021-12-31 | ₩93.36 Billion | +269.07% |
| 2020-12-31 | ₩25.30 Billion | -10.77% |
| 2019-12-31 | ₩28.35 Billion | -49.68% |
| 2018-12-31 | ₩56.33 Billion | +271.07% |
| 2017-12-31 | ₩15.18 Billion | -- |